Target RWE has rolled out a new patient-centric engagement platform, ‘engage’, which is designed to enhance the collection of patient-reported and clinician-reported outcomes.
This digital tool aims to facilitate a seamless capture of data in real-world evidence (RWE) studies.
According to Target RWE, the engage platform is set to revolutionise the way patient-reported outcome measures (PROs) as well as clinician-reported outcomes (ClinROs) are collected.
By leveraging digital technology, both patients and study sites can now easily capture protocol-specific data beyond the standard of care.
The company highlighted that 'engage' encourages active participation in Target RWE registries.
The platform is supported by study sites across the US, which are highly engaged in streamlining the data collection process for PRO measures.
One of the key features of 'engage' is the digital capture of patient consent forms.
The platform also integrates ClinROs into existing workflows and offers patient compensation through PayPal and Venmo for completed milestones.
This not only enhances patient engagement but also simplifies administrative processes for study sites.
Accessibility is a cornerstone of the platform, with patients able to securely contribute their health information through a mobile app or web portal.
The tool also allows for self-enrolment and submission of consent forms, providing study sites with a dashboard view of patient enrolment and milestones.
Target RWE CEO Derek Evans said: “By placing patients at the centre of our real-world registries, we are fostering improved patient engagement and acceleration of insights to transform clinical practice and improve patient outcomes.”
Furthermore, 'engage' offers an intuitive solution for study sites to customise study designs and data collection schedules.
With features such as and automated payments digital survey completion, the platform reduces administrative burdens and saves time, allowing for more efficient management of PROs, ClinROs, and biospecimens, the company added.
Notably, the collaborative nature of the platform ensures that the real-world data collected from Target RWE patient registries is of relevance, leading to more impactful RWE.
Target RWE chief medical officer Michael Fried said: “We are excited to launch engage, which will be instrumental in supporting our ongoing strategic partnership with the American Association of the Study of Liver Disease (AASLD) and their Cirrhosis Quality Collaborative (CQC) initiatives.
“Initial deployments of our new platform have already demonstrated improved patient adherence and increased completion rates of patient-reported outcomes among patients with cirrhosis in our TARGET-LIVER DISEASE registry.”
